We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1).
- Authors
Kimura, Tomoki; Nagata, Yasushi; Harada, Hideyuki; Hayashi, Shinya; Matsuo, Yukinori; Takanaka, Tsuyoshi; Kokubo, Masaki; Takayama, Kenji; Onishi, Hiroshi; Hirakawa, Koichi; Shioyama, Yoshiyuki; Ehara, Takeshi
- Abstract
Background: To investigate the maximum tolerated dose (MTD) and recommended dose (RD) of stereotactic body radiation therapy (SBRT) for centrally located stage IA non-small cell lung cancer (NSCLC). Methods: Five dose levels, ranging from of 52 to 68 Gy in eight fractions, were determined; the treatment protocol began at 60 Gy (level 3). Each dose level included 10 patients. Levels 1-2 were indicated if more than four patients exhibited dose-limiting toxicity (DLT), which was defined as an occurrence of a grade 3 (or worse) adverse effect within 12 months after SBRT initiation. MTD was defined as the lowest dose level at which more than four patients exhibited DLT. Results: Ten patients were enrolled in the level 3 study. One patient was considered unsuitable because of severe emphysema. Therefore, nine patients were evaluated and no patient exhibited DLT. The level 3 results indicated that we should proceed to level 4 (64 Gy). However, due to the difficulty involved in meeting the dose constraints, further dose escalation was not feasible and the MTD was found to be 60 Gy. Conclusions: The RD of SBRT for centrally located stage IA NSCLC was 60 Gy in eight fractions.
- Subjects
STEREOTACTIC radiotherapy; CANCER treatment; NON-small-cell lung carcinoma; ADJUVANT treatment of tumors; DOSE-response relationship (Radiation); RADIATION tolerance
- Publication
International Journal of Clinical Oncology, 2017, Vol 22, Issue 5, p849
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-017-1125-y